Same Peptide, Different Route: What Actually Changes

The short version

This is a research desk, not a store. It looks at three peptides that keep coming up in delivery-route conversations — BPC-157, CJC-1295, and semaglutide — and asks a specific, practical question: how does each one actually get into the body in the published research, and what changes when the route changes?

A peptide is a short chain of amino acids, the same building blocks as proteins, just smaller. That size is the whole problem with delivery. Stomach acid and gut enzymes are built to break amino-acid chains apart, so swallowing most peptides destroys them before they can do anything useful. Getting a peptide past the gut, under the tongue, or through the skin intact is a real engineering problem, not a marketing detail.

This page and the three that follow lay out what's actually been tested — injectable, oral, or otherwise — for each compound, and where the record runs out. No doses are given as advice anywhere on this site; every number here comes from a cited study.

What are research peptides?

Research peptides are synthetic versions of naturally occurring signaling molecules — short amino-acid chains that cells use to communicate with each other. BPC-157 is modeled on a fragment of a protein found in gastric juice. CJC-1295 is a modified version of a hormone the hypothalamus releases to trigger growth-hormone secretion. Semaglutide is a modified version of a gut hormone (GLP-1) that signals fullness after eating.

"Research peptide" is also a regulatory label. None of the three compounds on this desk is approved for over-the-counter human use in the form sold by research-chemical suppliers. Semaglutide is the exception in one specific sense: it is an FDA-approved prescription medicine ^[15], but only in its manufactured injectable and oral tablet forms — not in the unregulated "research-grade" vials sold outside a pharmacy. BPC-157 and CJC-1295 have no FDA approval in any form.

The distinction matters for a delivery-route discussion, because "oral semaglutide" is a real, engineered pharmaceutical product with published bioavailability data behind it ^[15]. "Oral BPC-157" and "sublingual CJC-1295" are marketing terms with no equivalent published human data behind them — a gap this desk states plainly rather than glossing over.

Delivery routes: what the record actually verifies

Route matters because a peptide's job is to reach a specific receptor intact, at a high enough concentration to do anything. Three routes come up constantly in research-peptide discussion, and the evidence behind each is wildly uneven across these three compounds.

Injectable (subcutaneous, intramuscular, or intravenous) is the only route with real pharmacokinetic data for BPC-157 and CJC-1295. The first formal ADME study of BPC-157 measured its behavior after intramuscular dosing in rats and dogs: an elimination half-life under 30 minutes, and intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs ^[3]. The first human data on BPC-157 came from an intravenous safety pilot in two adults, which found no adverse events at doses up to 20 mg ^[1] — intravenous, not oral or sublingual, and a 2025 review notes that only three such human pilot studies exist for BPC-157 in total ^[2]. CJC-1295's human pharmacology, likewise, comes entirely from subcutaneous dosing studies: single subcutaneous doses produced GH elevations lasting six days or more and a measured half-life of 5.8-8.1 days ^[9][10].

Oral is a real, verified route for exactly one compound here: semaglutide. Its oral tablet is co-formulated with an absorption enhancer (SNAC) that briefly protects a patch of stomach lining long enough for some of the peptide to cross into circulation — and even with that engineering, oral bioavailability is only about 0.4-1%, which is why strict fasted-dosing rules exist for the tablet ^[15]. Neither BPC-157 nor CJC-1295 has a comparable engineered oral formulation or published oral bioavailability figure in humans.

Sublingual and transdermal are, for BPC-157 and CJC-1295, the least-supported routes on this list. Peptides are large, charged molecules that do not cross the sublingual mucosa or intact skin efficiently without specific formulation chemistry, and the published research behind both compounds does not include a human sublingual or transdermal pharmacokinetic study for either one. That doesn't prove the routes do nothing — it means no public study has measured how much peptide, if any, reaches the bloodstream that way. Community reports of sublingual troches and transdermal creams exist in volume; verified absorption data does not.

How this desk reads the literature

Each compound page on this site opens with a plain-English summary, then works through what the compound is, how it's thought to work, what the actual trial or study record shows, and what people report using it for outside of clinical settings — labeled clearly as anecdotal. Two of the three compounds here, BPC-157 and CJC-1295, have a research base that is overwhelmingly preclinical or drawn from a handful of small human studies; the desk says so directly rather than smoothing it over. Semaglutide sits in a different evidence category entirely — multiple large randomized trials and an FDA-approved label — and gets treated accordingly.

Every quantitative claim on this site traces to a citation on the references page. None of it is medical advice, and no dose is ever suggested for a person to take.